A Part-randomised, Single Centre, Single Dose, Crossover,Phase I Study to Investigate the Impact of Changes to the Dosing Regimen on the Pharmacokinetic Profile of ODM-203 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs ODM 203 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms KIPEV
- Sponsors Orion Pharma
- 06 Feb 2018 Status changed from recruiting to completed.
- 19 Sep 2017 Status changed from not yet recruiting to recruiting.
- 09 Aug 2017 New trial record